411 results about "Neuroinflammation" patented technology

The invention discloses bifidobacterium breve and application thereof in relieving Alzheimer's disease, and belongs to the technical field of probiotics. The preparation method comprises the following steps: separating 18 bifidobacterium strains from feces of children aged 0-3 years old, analyzing and identifying the 18 bifidobacterium strains including bifidobacterium longum, bifidobacterium breve and bifidobacterium animalis, and screening out the bifidobacterium breve LE4 with potential Alzheimer's disease relieving capacity through in-vitro oxidation resistance and LPS (Lipopolysaccharide) removal capacity. The method comprises the steps of behavioral experiments (nesting experiments, open field experiments and water maze experiments), histopathologic analysis, molecular biological detection and the like. The multi-target AD intervention effects of improving the cognitive function, reducing A beta deposition and tau protein phosphorylation, relieving neuroinflammation, enhancing synaptic plasticity, repairing intestinal barriers, adjusting intestinal flora and metabolites and the like of the LE4 strain are comprehensively evaluated, and a new strategy is provided for promoting AD micro-ecological treatment.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention relates to the technical field of biological medicines, in particular to Hangzhou white chrysanthemum-derived exosome-like nano-vesicles as well as a preparation method and application thereof. Chrysanthemum morifolium ramat nano-vesicles are prepared from compositae plants through a high-speed centrifugation method, the average particle size of the nano-vesicles is 68 nm, and the Zeta potential is-19.50 + / -1.10 mV. The nano vesicles can effectively protect nerve cells and improve anxiety behaviors and cognitive impairment of SAE mice. The compound has a good application prospect in preparation of medicines for treating neuroinflammation and SAE.

The invention discloses preparation and application of dual-network hydrogel. The dual-network hydrogel comprises the following components: (Z1) a spinal cord acellular matrix network DSM formed by self-assembly of a spinal cord acellular matrix dSECM; and (Z2) a metal-polyphenol network MPN formed by coordination of metal ions and polyphenols; wherein the DSM and the MPN are cross-linked through hydrogen bonds to jointly form a double-network structure. DSM provides a microenvironment suitable for cell survival and growth for the dual-network hydrogel and induces stem cells to differentiate into neurons, and MPN provides the dual-network hydrogel with biological effects of inhibiting inflammation and accumulation of reactive oxygen species (ROS). The dual-network hydrogel has the advantages of the two components, the active component neurotrophic factor and the inhibitor loaded on the dual-network hydrogel can regulate and control immune response after SCI, improve neuroinflammation microenvironment and promote nerve repair, and a new strategy is provided for in-situ tissue repair of SCI.

The invention discloses application of a plant lactobacillus CCFM1357 to conversion of anthocyanin to generate various active metabolites, inhibition of a cGAS-STING pathway and enhancement of improvement of brain aging, and belongs to the technical field of microorganisms and the technical field of medicines. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention have the following effects: (1) a marker for relieving D-gal induced mouse brain senescence and a marker for relieving D-gal induced mouse brain senescence; (2) promoting and relieving D-gal induced mouse histopathologic characterization; (3) relieving D-gal induced mouse neuroinflammation; (4) relieving behavioral characterization of the D-gal induced aging mouse; and (5) a cGAS-STING signal channel is inhibited. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention can be used for a product for relieving brain aging, and have a huge application prospect.

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.

The present invention features compositions and methods for preventing or treating neuroinflammation, amyloidopathy or tauopathy by inhibiting Acyl-CoA:Cholesterol Acyltransferase activity, in particular with brain-permeable inhibitors encapsulated in a stealth liposome-based nanoparticle. Stealth liposome-based nanoparticles for reducing or attenuating amyloidopathy or tauopathy are also provided.

The present application relates to a diacetylene compound represented by formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a use of the compound, the pharmaceutically acceptable salt thereof, and the pharmaceutical composition. The compound, or the pharmaceutically acceptable salt thereof and the pharmaceutical composition comprising same can be used for preparing a drug for treating or relieving neuroinflammation and neurodegenerative diseases.

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention discloses a strain for preventing and treating Parkinson's disease as well as a composition, application and a product thereof, and relates to the technical field of microorganisms. The invention provides three strains from human milk, namely lactobacillus helveticus LV-20, plant lactobacillus LPP8 and lactobacillus fermentum PL-15, the invention further provides a composition capable of preventing and treating the Parkinson's disease, and the three strains can well prevent and treat the Parkinson's disease and can be used for preventing and treating the Parkinson's disease. The composition can significantly improve dyskinesia (such as static tremor, muscle stiffness, movement retardation, posture balance and the like), reduce neuron damage, significantly reduce alpha-syn deposition, reverse sensory function degradation and cognitive disorder, relieve sleep disorder, inhibit neuroinflammation and oxidative stress, reduce and repair intestinal barrier damage, relieve gastrointestinal dysfunction, and improve the curative effect. As probiotics or synbiotics, products for treating and preventing Parkinson's disease have a wide application prospect.

This invention relates to diselenylene-bridged mesoporous silica nanoparticles loaded with baicalin and their applications. The invention constructs a ROS-responsive, microglia-inspired Ba@Se-MSN&BV2 nanoplatform targeting the secondary phase of spinal cord injury. The BV2 cell membrane-mediated enrichment at the injury site, combined with the diselenylene-triggered, on-demand release of baicalin, enables targeted intervention in a highly oxidative and pro-inflammatory microenvironment. In vitro and in vivo studies show that Ba@Se-MSN&BV2 can alleviate oxidative stress and mitochondrial dysfunction, inhibit apoptosis, promote axonal and neuronal survival, and improve motor circuit function. This invention provides a new therapeutic target and research direction for neuroinflammatory injuries driven by redox homeostasis disruption, with significant clinical application prospects and social value.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

This invention discloses the application of the inflammasome NLRP6 as a target in screening drugs for treating epilepsy, and the application of NLRP6 expression inhibitors in the preparation of drugs for treating epilepsy. This invention reveals for the first time the role of the inflammasome NLRP6 in epileptic neuroinflammation. This invention identifies NLRP6 as a key regulator of neuroinflammation in epilepsy and investigates its role in activating the caspase-1 / IL-1β / IL-18 signaling pathway. Knockdown of NLRP6 can improve the damaging effects of epilepsy on neurons, thereby improving seizures; overexpression of NLRP6 may exacerbate seizures, neuronal damage, and neuroinflammatory responses. This invention provides a new potential target for epilepsy treatment, offering new research ideas and directions.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The invention discloses an application of abscisic acid in preparation of a medicine for improving secondary brain injury after cerebral hemorrhage, the abscisic acid can relieve neuroinflammation and improve neurological function recovery by repairing microglial cell lysosome functions, enhancing phagocytic ability and promoting hematoma removal, and a new medicine strategy is provided for cerebral hemorrhage treatment.

The present application relates to the technical field of probiotics, and particularly relates to a Bifidobacterium breve strain and application of the Bifidobacterium breve strain in prevention or treatment of neurodegenerative diseases and neuroinflammation related to neurodegenerative diseases. Bifidobacterium breve ) BKR006, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) (address: No. 1, Xili Beichen, Chaoyang District, Beijing), and the preservation number is CGMCC No. 36096. The strain in the present application is proved in animal experiments that the strain can not only significantly improve the cognitive function and A beta pathology of AD model animals, but also effectively inhibit neuroinflammation in PD models and improve related cognitive impairment, and has a broad spectrum of neuroprotective effect and good development and application prospect.

The invention relates to methods and compositions for preventing or treating a neuropathology in a subject associated with or induced or caused by a P. gingivalis infection, preventing the deposition of or reducing the level of P. gingivalis gingipain in neuronal tissue, delaying the onset of a P. gingivalis-induced or associated neuropathology, for preventing or slowing the rate of abnormal protein deposition in the neuronal tissue, and / or reducing neuroinflammation, the methods comprising administering an RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, wherein the polynucleotide is capable of being translated in a mammalian cell.

The invention relates to hydroxylated polyamide-amine dendrimer integrated drug-loaded nanogel as well as a preparation method and application thereof. The drug-loaded nanogel comprises third-generation polyamide-amine dendrimer integrated nanogel modified by double bonds and high-density hydroxyl groups, MnO2 nanoparticles and quercetin, wherein the nanogel is loaded with MnO2 nanoparticles in situ, and quercetin is physically wrapped in the nanogel. The drug-loaded nanogel disclosed by the invention can enhance a blood-brain barrier penetrating effect, regulate microglial cells and neurons in a double-target manner and remodel a brain inflammation microenvironment, so that neuroinflammation and dyskinesia of a Parkinson's disease model mouse are relieved, and the curative effect of the Parkinson's disease is improved. The compound has good development prospect and application value in treatment of Parkinson's disease or other neurodegenerative diseases.

The application relates to the technical field of targeted drugs, in particular to an organic compound and application of the organic compound in preparation of a PET probe for targeting 18kDa translocation protein and in pharmacy. 18 Or F. Compared with a conventional PET probe, the organic compound has the targeting TSPO characteristic, can be used for preparing the PET probe for targeting TSPO, is stable in in-vivo plasma metabolism, has lower non-specific uptake, and can be used for diagnosis, scientific research and drug preparation of neuroinflammation.

The invention discloses an mGluR5 small-molecule allosteric modulator and application thereof in inhibition of neuroinflammation, and belongs to the technical field of neuropharmacology and anti-inflammatory drug research, two mGluR5 small-molecule allosteric modulators are obtained by virtual screening through an allosteric pocket targeting mGluR5, the structural formulas of the two mGluR5 small-molecule allosteric modulators are shown in the specification, and the structural formula of the mGluR5 small-molecule allosteric modulators is shown in the specification. The mGluR5 micromolecule allosteric modulator can be used for inhibiting microglial cell inflammation, and can effectively relieve LPS-induced microglial cell NO release.

The application discloses a nano guanido drug system and a preparation method and application thereof, and relates to the technical field of medicine, in particular to a GCOF DHM @CAQK platform, can efficiently deliver drugs to a TBI injury site, can accumulate in a TBI brain injury area, can inhibit neuroinflammation, oxidative stress and protect neuron cells after TBI, can precisely intervene in secondary injury of TBI, and provides a new strategy for improving the prognosis of patients.

The invention provides a traditional Chinese medicine preparation for improving or treating cognitive impairment, and relates to the technical field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine preparation is prepared from morinda officinalis, eclipta, semen boitae, fructus alpiniae oxyphyllae, bighead atractylodes rhizome, valerian, turmeric, rhizoma acori graminei, leech, rhizoma anemarrhenae, dendrobium officinale, endothelium corneum gigeriae galli, hematoxylon and honey-fried licorice root. The traditional Chinese medicine preparation shows remarkable neuroprotection and cognition improvement effects on the cell level and the animal level, in the cell level, the preparation can effectively resist Abeta1-42 induced cell damage, and the protection effect is achieved through multiple ways of improving the cell activity, enhancing the oxidation resistance, inhibiting neuroinflammation and the like; in animal experiments, the preparation can comprehensively improve cognitive impairment of APP / PS1 model mice, including relieving behavioral abnormality, improving spatial learning and memory ability, enhancing new object recognition ability, and effectively reducing deposition of A beta in hippocampus on a molecular level. The invention provides a new thought for improving or treating cognitive impairment.

The application discloses application of PTN in preparation of products for treating cognitive impairment caused by severe infection. The inhibitor of PTN provided by the application can inhibit chronic neuroinflammation, thereby preventing and inhibiting formation and development of late cognitive impairment caused by severe infection, and meanwhile, inhibition of expression or function of PTN can effectively block damage of infiltrating macrophages to microglia cells, thereby providing a new direction for treatment of related diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with CEF in preparation of anti-PD drugs. The research finds that the hUC-MSCs and the CEF are combined to treat the PD, and the treatment effect is better than that of single hUC-MSCs or CEF, especially the treatment effect of Parkinson patients accompanied by intestinal diseases. The composition plays a role through the following ways: 1) repairing an intestinal barrier, and reducing endotoxin and inflammatory factors from entering a whole body system; 2) abnormal aggregation and propagation of alpha-syn are directly inhibited; 3) the composition of intestinal flora is regulated, excessive proliferation of pro-inflammatory flora is inhibited, and generation and secretion of SCFAs are promoted; and (4) the microenvironment in the brain is improved, neuroinflammation is relieved, and neural restoration is promoted. The invention provides a new thought for treatment of Parkinson's disease.

The application provides application of dimethyl itaconate in prevention and treatment of chronic stress-induced anxiety. The application finds that dimethyl itaconate can inhibit excessive activation of microglial cells in a stress state, improve mitochondrial structure and function abnormalities of the microglial cells, and reduce expression of a lysosome marker CD68, so as to inhibit central nervous inflammation, maintain central nervous immune homeostasis, prevent and relieve anxiety-like behavior induced by chronic stress, and effectively prevent and relieve occurrence and development of chronic stress-induced anxiety (generalized anxiety disorder).

The present invention relates to a composition for preventing or treating bladder diseases, a composition for preventing or treating neuropathic pain, neuroinflammation or inflammatory skin diseases, or the therapeutic use of a novel compound YJ102, the compound YJ102 of the present invention inhibits neuropathic pain due to various reasons, ameliorates urination disorders due to spinal cord injury, restores bladder hypertrophy and bladder function, inhibits erythema and keratinogenesis, which are main symptoms of psoriasis, in a psoriasis animal model, and has a superior effect than conventional drugs. The composition can inhibit increase of the thickness of the epidermal layer and spleen hypertrophy caused by psoriasis, and can be used for treating various difficult nervous system diseases or bladder diseases.

The present invention relates to: a water-soluble substituent-based novel compound having high solubility and a method for preparing same. The novel compound having high solubility of the present invention has repeating units represented by chemical formula 1, and has an excellent anti-inflammatory effect and an excellent effect on diseases caused by oxidative stress and neuroinflammatory diseases, and thus is useful as a health food or a pharmaceutical composition. [Chemical formula 1]